CHRS
$1.71+0.05 (+3.12%)
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating f...
Recent News
Coherus Oncology Pivots to Immuno-Oncology, Touts LOQTORZI Growth and New Pipeline at Citizens Conf.
Coherus Oncology (NASDAQ:CHRS) used its presentation at the Citizens Life Sciences Conference to outline its transition into what CEO Denny Lanfear described as an “innovative oncology company focused on overcoming immune resistance in cancer,” centered on a commercial PD-1 therapy and two pipeline
Coherus Oncology Inc (CHRS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Coherus Oncology Inc (CHRS) reports significant revenue growth and a 90% reduction in debt, positioning itself for future innovation and market expansion.
Coherus Oncology Q4 Earnings Call Highlights
Coherus Oncology (NASDAQ:CHRS) outlined progress on its transition to an “innovative oncology” company during its fourth-quarter and full-year 2025 earnings call, highlighting a growing commercial base in nasopharyngeal carcinoma (NPC), an expanding clinical development plan focused on overcoming im
Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -9.68% and -2.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Coherus Oncology: Q4 Earnings Snapshot
REDWOOD CITY, Calif. AP) — Coherus Oncology, Inc. CHRS) on Monday reported a loss of $37.6 million in its fourth quarter.